Cladribine + Low-dose Cytarabine + Venetoclax alternating with Azacitidine + Venetoclax (higher-risk CMML/MDS)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-05 — A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts: Phase II trial (trial-early) evaluating an alternating regimen of cladribine + low-dose cytarabine + venetoclax with azacitidine + venetoclax in higher-risk MDS with excess blasts and/or higher-risk CMML — novel multi-agent strategy layering induction-style chemo onto an HMA + BCL-2 backbone in the MDS/MPN overlap population. (novelty: 3)
Open questions
Related
Contributing findings
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
05-jun-2026
novelty 3
per-area 3
introduces